Syntara (ASX: SNT)

Blood cancer patients undergoing chemotherapy could soon have a reduced dependence on blood transfusions thanks to a new clinical study announced, run in partnership between biotech company Syntara (ASX: SNT), the University of Newcastle and the Australasian Leukaemia and Lymphoma Group (ALLG).  The Phase 2 clinical study has been backed by a $0.83m grant to

Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in clinical-stage drug developer Syntara to 19.24%, fresh off the commencement of a Phase 2a clinical study that has the potential to become a new treatment for patients diagnosed with myelofibrosis (bone marrow cancer). The combination

Clinical-stage biotech company Syntara (ASX: SNT) has stepped into a transformative year with a renewed focus on drug development. Entering 2024, the Company took the “new year, new me” concept seriously, divesting its Pharmaxis mannitol business and rebranding as Syntara with new leadership to include high profile biotech experts that have commercialised drugs for Big

Beyond the searing pain of burns, permanent scarring of the skin has a devastating lifelong impact on quality of life. Imagine reaching up for the top shelf and having a sharp pain surge down your arm and back. Unfortunately this is the reality for millions of burn victims where skin does not heal with the

Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where

Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling  Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated

With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers.  The definitive sale agreement of its

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%. 

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis (ASX: PXS) has quickly jumped forward in the commercialisation process having been cleared by the US Food and Drug Administration (FDA) to commence a combination arm of the trial. The clearance of the amended trial

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis.  The data revealed 60% of trial patients experienced a significant improvement in

The world is one step closer to scarless healing with clinical data released by the University of Western Australia (UWA) where their trials led by Professor Fiona Wood AM have delivered highly encouraging results from a topical cream that can reduce scar tissue formation.  The vital ingredient within the cream used is the drug PXS-6302

A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to access a new treatment which has already shown to be effective in a small group of patients undergoing treatment of PXS-5505 in Phase 2 clinical trials. Myelofibrosis is a rare cancer of the bone marrow

Balance sheets don’t tell the whole story. This is especially true for biotech companies where pre-revenue businesses can still be worth billions of dollars with the innovative medicines they are creating. On a macro level, biotech companies outperformed the S&P 500 and both pharmaceutical and medtech sectors in terms of total returns to shareholders over

There is an urgent need for better treatment for myelodysplastic syndrome (MDS), a type of blood cancer, and new research published in prestigious scientific journal Nature Communications suggests a breakthrough could be coming. Researchers at the University of Heidelberg in Germany have reported results claimed to be “the best we have ever observed in our

As a medical research company, successful trial outcomes are a must but business acumen in understanding the market is no less important either. For clinical stage biotech company Pharmaxis (ASX: PXS), their latest addition to the Board of Directors line-up will offer them the best of both worlds with the appointment of healthcare investment researcher

Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical

While clinical trials could be tricky for companies who struggle to convince fearful and pessimistic volunteers to participate, luckily this is not the case for clinical stage drug developer Pharmaxis (ASX: PXS). The Company has wrapped up patient recruitment of its topical anti scarring drug PXS-6302, with the last of the 42 patients dosed earlier

Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer, the US Food & Drug Administration (FDA) could soon be the next stop for biopharmaceuticals company Pharmaxis (ASX: PXS) fresh off their poster presentation at the American Society of Hematology (ASH) conference.  Hosted in New

When it comes to biotech investing, the value opportunities in Australia attract many of the world’s smartest investors. Amongst them, Platinum Asset Management (ASX: PTM) has joined a growing list of institutions taking a substantial stake in a little-known Aussie biotech set to announce hugely-anticipated clinical trial results within the next few months.  With more

More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is a progressive disorder which currently has no cure and few treatments. However, researchers at Parkinson’s UK have a new reason to hope. They are investigating whether early detection and treatment of certain sleeping disorders might

For patients given less than five years to live after being diagnosed with myelofibrosis, there is a new flicker of hope after clinical stage drug development company Pharmaxis (ASX: PXS) reported encouraging interim data from their Phase 2 trials. Myelofibrosis is a rare cancer of the bone marrow affecting 15 per 1 million people worldwide.

Patients who suffer from permanent scars are one step closer to a treatment that could alleviate both the physical and mental effects thanks to promising interim data released by clinical stage pharmaceuticals company Pharmaxis (ASX: PXS) and a team at the University of Western Australia, led by Professor Fiona Wood AM. The trial of drug

This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s fit into the equation alongside cancer, skin scarring and cystic fibrosis? Unpacking the Pharmaxis investment case reveals an agile company with more than one trick up their sleeves, keeping business buoyant whilst other biotechs list

Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX: PXS) technology. In August, 2021 Aptar signed an exclusive option agreement to Pharmaxis’ “Orbital” technology, handing over USD $250,000. Now, a little under a year later, Aptar is deploying USD $2.5 million to exercise the

At eight years old, Ben Smith was involved in an accident leaving him with severe burns to 55% of his body.  Whilst the event itself is now 20 years in the past, Ben is reminded of it every day thanks to the scars left behind.  Tissue scarring is a vital part of wound healing. However,

How does a company with a lead asset cancer drug also get into dermatology?  What does blood cancer and keloid scars have in common?  The answer is: fibrosis.  Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how

Despite what it may look like, investing in biotechs is more science than art. The sector holds intrinsically higher risk, but investing in it can be well worth it to those willing to take the plunge. In fact, over the last twenty years biotech firms have outperformed the S&P 500 and both the medtech and

The skin is one of the most overlooked, complex and essential organs. It is the body’s first line of defence against dehydration, infection, and injury and plays a role in thermoregulation, vitamin D absorption and the nervous system.   Throughout the course of life we are bound to end up with scars from adventures and mishaps,

Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,

The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that we may soon find resolutions to the complicated medical challenges of today.  The competitive nature of the space means that whoever is first to market has a clear advantage. Clinical stage pharmaceutical company Pharmaxis (ASX:

Things are well and truly on track for clinical stage pharmaceutical company Pharmaxis (ASX: PXS), a sentiment confirmed by CEO Gary Phillips in his shareholder address in their recent quarterly results. The Company has made significant progress in three clinical trial programs, with plenty on the horizon for their preclinical pipeline too.  Lead asset PXS-5505

In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline.  For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the

Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted to its projects, this time from the Government to apply work towards skin diseases and pancreatic cancer.  The NMHRC Drug Development Grant scheme is an Australian government initiative set up to provide financial aid to

When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world.  By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on 

Clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is in a transformation phase as their clinical pipeline progresses towards multiple value inflection points.  With two products already on market, the Company has a great base from which to fund their ongoing clinical product development. Adding to that, the company has just completed a capital raise via

Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the

Clinical stage drug development company, Pharmaxis (ASX: PXS) is making a name for themselves in the oncology sector, with their lead asset oncology drug yielding promising results in numerous studies.  PXS-5505, a drug designed for the treatment of rare blood cancer myelofibrosis is built on Pharmaxis’ proprietary platform, harnessing the power of enzyme inhibition to

Whilst key opinion leaders worldwide are following the Pharmaxis (ASX: PXS) story, Professor Fiona Wood has become an integral part of it.  Following the news out of Rochester University that their myelofibrosis drug, PXS-5505, has a potential significant disease modifying role in other cancers comes another key announcement for the company, this time regarding their

With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, a

Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before.  More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events

Sitting down with Gary Phillips reminds me of chatting to my favourite chemistry teacher in high school. Not that you’d usually compare a biotech company CEO to a past teacher but much like Mr McLeod, Gary has the unique ability to get you excited about science. Gary heads up Pharmaxis (ASX: PXS), a Sydney-based biotechnology

Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights

Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir.   Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,

The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the significant success they experienced with a large holding of Avita Medical. Originally based in Hong Kong but now also with an office in Sydney, Karst’s investment focus includes the healthcare, biotech and pharmaceuticals industry which

In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one.  In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million

One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS).  The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play

The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment Bronchitol is rapidly emerging as the preferred treatment by CF sufferers in the United States. Researched and manufactured in Australia, Bronchitol gained commercial approval from the US Food and Drug Administration (FDA) in October 2020